Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM1811-03 in advanced solid tumors and cutaneous T-cell lymphoma
NCT05569057Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suvicitumab in solid tumor and cutaneous T-cell lymphoma (CTCL), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Incidence Rate of Dose-Limiting Toxicity at 28 days and Objective Response Rate at 1 year. Status: unknown.
02
Drugs
suvicitumab
03
Conditions
solid tumorcutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05569057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569057.